Skip to main content

Advertisement

Figure 5 | Radiation Oncology

Figure 5

From: Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients

Figure 5

Disease-free survival rates according to the combined biomarker prognostic index (P21 and CD44v6). High risk involves having both of the two risk factors: low P21 expression and high CD44v6 expression. Intermediate risk involves having either low P21 expression or high CD44v6 expression. Low risk involves having neither low P21 expression nor high CD44v6 expression.

Back to article page